$44.140
+1.170 (+2.65%)收盤時
BSX 資訊
BSX 事件
Boston Scientific Appoints Joseph Fitzgerald as COO
Boston Scientific announced the appointment of Joseph Fitzgerald to executive vice president and COO, effective Jan. 1, 2027. In this role, Fitzgerald will oversee the company's global operations, business units and regions. In connection with Fitzgerald's appointment, Boston Scientific will establish three reportable segments: Interventional Therapies, Rhythm Solutions and MedSurg also effective Jan. 1.
Elutia Completes BioEnvelope Sale, Receives $8M
Elutia (ELUT) has received the full $8M held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific (BSX). The payment was made following an indemnity holdback period that began with the October 1, 2025 closing of the $88M transaction. The company believes it is funded through the first full year of the NXT-41x commercial launch and into 2029, without the need for an equity offering. The regulatory process remains on track and Elutia continues to expect a favorable FDA clearance decision for NXT-41x in the first half of 2027. NXT-41x is the company's next-generation antibiotic-eluting surgical matrix. It is being developed for use in the $1.5B U.S. plastic and reconstructive surgery market.
Boston Scientific Shares Rise 4.76%
Moderately bullish activity in Boston Scientific (BSX), with shares up $2.04, or 4.76%, near $45.02. Options volume running well above average with 62k contracts traded and calls leading puts for a put/call ratio of 0.68, compared to a typical level near 0.93. Implied volatility (IV30) is higher by 1.3 points near 37.78,and above the 52wk median, suggesting an expected daily move of $1.07. Put-call skew steepened, indicating increased demand for downside protection.
Dow Jones Drops Over 500 Points as Oil Prices Rise Reviving Inflation Concerns
The major averages were broadly lower near noon, with the Dow Jones losing over 500 points as a renewed jump in oil prices and escalating Middle East tensions revive inflation concerns.The rise in oil prices is particularly problematic coming after Friday's stronger-than-expected August jobs report. The U.S. added 162,000 jobs, nearly three times economists' expectations, pushing markets to increase bets that the Federal Reserve could raise rates at its September 16 meeting. The probability of a hike is now around 60%, while the 10-year Treasury yield has climbed to roughly 4.8%.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:An Amazoncargo plane overshot the runway at Miami International Airport this weekend,Qualcommannounced awith AmazonGE AerospaceConsolidated Precision Products for $11.75BBoston Scientificsaid it isits Q3 and FY26 net sales and adjusted earnings per share guidanceNovartisshares fell after its Phase 3 HARBOR study for DM12. WALL STREET CALLS:Intelto Outperform at Northland after "material" turnaround progressPelotonto Underweight at Morgan StanleyAirbnbto Outperform at Raymond JamesBest Buyto Neutral at DA DavidsonSpaceXwith a Buy at Pivotal Research3. AROUND THE WEB:Nvidia-backedFirmus signed a multi-year deal with OpenAI to supply computing capacity to two Malaysian data centers, Reuters reportsAhead of Oura's upcoming IPO filing, Robinhoodhas been listed as an underwriter, WSJ saysNovo Nordiskhas halted two trials testing of ziltivekimab, its experimental heart disease medicine, would help patients with heart failure, Bloomberg reportsAir Cairo is set to purchase 15 AirbusA320 family jets, with the deal expected to be finalized as soon as this week, Bloomberg saysThe Independent Communications Authority of South Africa, South Africa's telecommunications regulator, plans to investigate prices charged by providers such as Netflixand Meta'sWhatsApp, Bloomberg reports4. MOVERS:Roivant Sciencesgains in New York after announcing its Phase 3 PHocus clinical trialPharvarisincreases in New York after announcing its CHAPTER-3 Phase 3 studyD-Wave Quantumhigher afterwith the U.S. Department of CommerceSigma Lithiumfalls after a preliminary judicial rulingBeam Therapeuticslower after announcingfrom its Phase 1/2 trial evaluating BEAM-3025. EARNINGS/GUIDANCE:United Natural Foodsand provided guidance for FY27ABMand raised its outlook for FY26, with CEO Scott Salmirs highlighting "record quarterly revenue, robust EPS growth and substantial cash generation"Solaris Energyfor Q3 and Q4General Millsfor FY27GameStop, with EPS higher year-over-yearINDEXES:Near midday, the Dow was down 562.84, or 1.05%, to 52,851.41, the Nasdaq was down 23.20, or 0.09%, to 26,483.79, and the S&P 500 was down 27.48, or 0.36%, to 7,691.12.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。